Biotechnology firm Biocon on Friday said its board has approved to raise up to Rs 600 crore in one or more tranches on a private placement basis. The company's board has approved issuance of commercial papers up to an amount not exceeding Rs 600 crore in one or more tranches on private placement basis, the company said in a regulatory filing.
It, however, did not disclose reasons for raising the capital.
ADVERTISEMENT
RECOMMENDED FOR YOU
Indigo Delhi-Pune Flight Faces Over Four-Hour Delay As Pilot Falls Sick Before Takeoff
Jul 05, 2025
Biocon's Fundraise To Provide Investor Exits Closes Listing Window For Unit
Jun 17, 2025
 Syngene is a subsidiary of Biocon Ltd..jpg?rect=0%2C0%2C3500%2C1969&w=75)
Biocon Shares Trade Higher After Board Sets Floor Price For Rs 4,500-Crore QIP
Jun 17, 2025
Biocon Sets Floor Price At Rs 340.20 For Rs 4,500-Crore QIP
Jun 16, 2025
POPULAR
1
Mid-Cap Stocks To Buy, Sell Or Hold: Godawari Power, NMDC, And Paradeep Phosphates
2
Buy, Sell Or Hold PSU Stock: Canara Bank, Bharat Dynamics And Bank Of Baroda In Focus
3
Stock Market Live: Sensex Falls Over 300 Points, Nifty Below 25,100 As Wipro, Infosys, Tech Mahindra Drags
4
Metals And Mining Q1 Preview: Ferrous To Shine, Non-Ferrous To See Lower Realisations
5